

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS**

1. *(previously presented)*: A method for producing a population of mononuclear cells overexpressing IL-10 polypeptide which cells (i) are not selected on the basis of specificity for a predetermined antigen and (ii) treat an inflammatory disease or condition in an antigen-independent manner, the method comprising:
  - (a) modifying at least a portion of a mammalian peripheral blood mononuclear cell population,  
among which cells lymphocytes are not selected or enriched on the basis of antigen specificity,  
by introducing into said cells an expression construct that comprises a nucleotide sequence encoding an IL-10 polypeptide; and,
  - (b) recovering, from said modified mononuclear cells, cells that
    - (i) overexpress the IL-10 polypeptide, and
    - (ii) are not specific for a predetermined antigen,thereby producing said population of mononuclear cells overexpressing IL-10 that are capable of treating said inflammatory disease.
2. *(previously presented)*: A method according to claim 1, wherein the expression construct is introduced into an enriched fraction or subset of said peripheral blood mononuclear cell population.
3. *(previously presented)*: A method according to claim 2, wherein the enriched fraction or subset is selected from the group consisting of (i) lymphocytes, (ii) macrophages, (iii) monocytes and (iv) dendritic cells.
4. *(previously presented)*: A method according to claim 1, wherein prior to the introducing step (a), the mononuclear cells are induced to, or allowed to, proliferate.
5. *(previously presented)*: A method according to claim 4, wherein the mononuclear cells are induced to proliferate by a proliferating agent.

6. *(previously presented)* A method according to claim 5, wherein the proliferating agent is one or more of
- (a) an anti-CD3 antibody;
  - (b) an anti-CD28 antibody; or
  - (c) phytohemagglutinin.
7. *(previously presented)* A method according to claim 1, wherein subsequent to step (a), the modified mononuclear cells are fractionated to yield an enriched cell fraction or subset.
8. *(previously presented)* A method according to claim 7, wherein the fraction or subset comprises enriched
- (i) lymphocytes or a subset thereof,
  - (ii) macrophages or monocytes, or
  - (iii) dendritic cells.
9. *(previously presented)* A method according to claim 1, wherein subsequent to step (a), the modified mononuclear cells are enriched for cells that overexpress the IL-10-encoding nucleotide sequence.
10. *(withdrawn; previously presented)* A method for producing a pharmaceutical composition comprising mononuclear cells overexpressing IL-10, which method comprises
- (a) producing the mononuclear cells overexpressing IL-10 in accordance with claim 1, and
  - (b) combining said cells with an acceptable pharmaceutical carrier.
11. *(withdrawn)* A composition comprising mononuclear cells that are not selected to be specific for a predetermined antigen which cells are modified to comprise an IL-10 transgene.
12. *(withdrawn)* A T lymphocyte composition that is a fraction of the mononuclear cells according to claim 11, which T cells comprise said IL-10 transgene.
13. *(withdrawn)* A T lymphocyte composition according to claim 12, wherein the T cells functionally mimic regulatory T cells in that they inhibit:
- (a) proliferation of autologous responder cells, and/or
  - (b) production of pro-inflammatory cytokine IL-12 by dendritic cells.
14. *(withdrawn)* A pharmaceutical composition comprising the composition according to claim 1, and a pharmaceutically acceptable carrier.

15. *(withdrawn)* A method of treating a disease or condition associated with undesired activation and/or expansion of T cells, which method comprises administering an effective amount of a pharmaceutical composition according to claim 14 to a subject suffering from said disease or condition.

16. *(withdrawn)* A method according to claim 15, wherein the disease or condition is a Th1-mediated disease or condition.

17. *(withdrawn)* A method according to claim 16, wherein the Th1-mediated disease or condition is Crohn's disease, reactive arthritis, insulin-dependent diabetes, colitis, pancreatitis, an inflammatory lung disease, an inflammatory eye disease, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, chronic articular rheumatism, contact dermatitis, psoriasis, graft rejection, graft-versus-host disease, or sarcoidosis.

**18. to 19. Canceled**

20. *(previously presented)* A method according to claim 3 wherein the enriched lymphocyte subset comprises an enriched population of B lymphocytes, T lymphocytes or CD4<sup>+</sup> lymphocytes.

21. *(previously presented)* A method according to claim 8 wherein the enriched lymphocyte subset comprises an enriched population of B lymphocytes, T lymphocytes or CD4<sup>+</sup> lymphocytes.

**22. Canceled**

23. *(withdrawn)* A method according to claim 16 wherein the Th1-mediated disease is an inflammatory disease.